A Living Donor Liver Transplantation after Therapeutic Plasmapheresis in a Patient with Positive HLA Crossmatch.
- Author:
Serim KIM
1
;
Young Sook CHOI
;
Won Hyuk CHOI
;
Seong Hwan CHANG
;
Ik Jin YUN
;
Eun Young SONG
Author Information
1. Department of Laboratory Medicine, College of Medicine, Konkuk University, Seoul, Korea. eysongmd@hanmail.net
- Publication Type:Case Report
- Keywords:
Positive HLA crossmatch;
Therapeutic plasmapheresis;
Living donor liver transplantation
- MeSH:
Hepatitis B, Chronic;
Humans;
Liver Cirrhosis;
Liver Transplantation*;
Liver*;
Living Donors*;
Lymphohistiocytosis, Hemophagocytic;
Male;
Middle Aged;
Plasmapheresis*;
Tissue Donors;
Transplants
- From:Korean Journal of Blood Transfusion
2007;18(3):260-264
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A positive HLA crossmatch in cadevaric liver transplantation is relatively acceptable, but in living donor liver transplantation (LDLT) using relatively small sized grafts, the rejection rates were higher in positive crossmatchcases than in negative cases, as described in several previous reports. We report a case of LDLT performed with therapeutic plasmapheresis, in a recipient with a positive HLA crossmatch to donor before transplantation. The patient was a 56-year-old male patient with liver cirrhosis (UNOS status IIA, MELD score 28) caused by chronic hepatitis B. The HLA crossmatch results were 1:2 and 1:8 positive for NIH-CDC (complement dependent cytotoxicity) and AHG-CDC, respectively. The flow cytometric crossmatch (FCXM) was also positive (T-MFI ratio 9.0 and B-MFI ratio 3.4). With 5 cycles of preoperative therapeutic plasmapheresis, the HLA crossmatch converted to negative and liver transplantation was performed. The liver function of the patient was well maintained for 5 months, without any sign of hyperacute or acute rejection. However, the patient eventually died from suddenly occurred infection-associated hemophagocytic syndrome at 5 months after surgery. Therapeutic plasmapheresis can be considered as one of therapeutic options for LDLT patients with a positive HLA crossmatch to donor.
